RS51122B - Primena 5`-metiltioadenozina(mta) kod prevencije i/ili lečenja autoimunih bolesti i/ili pri odbacivanju transplantata - Google Patents

Primena 5`-metiltioadenozina(mta) kod prevencije i/ili lečenja autoimunih bolesti i/ili pri odbacivanju transplantata

Info

Publication number
RS51122B
RS51122B RSP-2009/0549A RSP20090549A RS51122B RS 51122 B RS51122 B RS 51122B RS P20090549 A RSP20090549 A RS P20090549A RS 51122 B RS51122 B RS 51122B
Authority
RS
Serbia
Prior art keywords
prevention
treatment
mta
autoimmune diseases
transplant rejection
Prior art date
Application number
RSP-2009/0549A
Other languages
English (en)
Inventor
Pablo Villoslada Diaz
Matias Avila Zaragoza
Beatriz Moreno Bruna
Fernando Corrales Izquierdo
Carmen Berasain Lasarte
Elena Ruiz Garcia-Trevijano
Original Assignee
Proyecto De Biomedicina Cima S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima S.L. filed Critical Proyecto De Biomedicina Cima S.L.
Publication of RS51122B publication Critical patent/RS51122B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Upotreba 5'-metiltioadenozina (MTA), njegovih farmaceutski prihvatljivih soli i/ili prolekova, gde su navedeni prolekovi esteri ili amidi MTA koji, nakon što su primenjeni na osobi, daju MTA, direktno ili indirektno, navedenoj osobi, za pripremu leka za (i) prevenciju i/ili liječenje autoimune bolesti ili za (ii) prevenciju i/ili liječenje odbacivanja transplantata.Prijava sadrži još 6 patentnih zahteva.
RSP-2009/0549A 2005-03-17 2005-03-17 Primena 5`-metiltioadenozina(mta) kod prevencije i/ili lečenja autoimunih bolesti i/ili pri odbacivanju transplantata RS51122B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/ES2005/000139 WO2006097547A1 (es) 2005-03-17 2005-03-17 Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes
EP05728461A EP1891961B1 (en) 2005-03-17 2005-03-17 Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection

Publications (1)

Publication Number Publication Date
RS51122B true RS51122B (sr) 2010-10-31

Family

ID=36991307

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0549A RS51122B (sr) 2005-03-17 2005-03-17 Primena 5`-metiltioadenozina(mta) kod prevencije i/ili lečenja autoimunih bolesti i/ili pri odbacivanju transplantata

Country Status (19)

Country Link
US (1) US7820637B2 (sr)
EP (1) EP1891961B1 (sr)
JP (1) JP2008533107A (sr)
CN (1) CN101141970A (sr)
AT (1) ATE442854T1 (sr)
AU (1) AU2005329287B2 (sr)
BR (1) BRPI0520129A2 (sr)
CA (1) CA2601557A1 (sr)
CY (1) CY1109539T1 (sr)
DE (1) DE602005016729D1 (sr)
DK (1) DK1891961T3 (sr)
ES (1) ES2334924T3 (sr)
HR (1) HRP20090646T1 (sr)
MX (1) MX2007011327A (sr)
PL (1) PL1891961T3 (sr)
PT (1) PT1891961E (sr)
RS (1) RS51122B (sr)
SI (1) SI1891961T1 (sr)
WO (1) WO2006097547A1 (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
WO2010142827A1 (es) 2009-06-11 2010-12-16 Proyecto De Biomedicina Cima, S. L. Propiedades neuroprotectoras de 5'-metiltioadenosina
WO2011054990A2 (es) * 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Composiciones para la inhibición y/o bloqueo de la transición epitelial-mesenquimal
JP5801572B2 (ja) * 2011-03-03 2015-10-28 シーシーアイ株式会社 ＰＰＡＲγ活性化剤
CN105255887B (zh) * 2015-07-17 2018-05-18 四川大学 一种重组慢病毒及其在制备治疗可卡因成瘾的药物中的用途
EP3946352A4 (en) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
CN114515294A (zh) 2022-02-25 2022-05-20 浙江中医药大学 5’-甲基硫代腺苷在制备肥胖抑制药物或保健品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1193529B (it) 1980-04-22 1988-07-08 Bioresearch Srl Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo
IT1227049B (it) * 1988-07-29 1991-03-14 Bioresearch Spa Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
SK48199A3 (en) 1996-10-16 2000-01-18 Icn Pharmaceuticals Purine l-nucleosides, analogs and uses thereof
NZ504465A (en) * 1997-10-14 2001-11-30 Welfide Corp 1-Phenylacylamino substituted piperazine derivatives which are 4-substituted by a heteroaryl group
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
JP2001072660A (ja) * 1999-09-08 2001-03-21 Welfide Corp ＴＮＦ−α産生抑制剤および／またはＩＬ−１０産生促進剤
DK1252157T3 (da) * 2000-01-31 2004-10-25 Pfizer Prod Inc Pyrimidin-carboxamider anvendelige som inhibitorer af PDE4 isozymer
WO2001066518A1 (fr) * 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. E-ALCOOLS PHENYL-PROSTAGLANDINE φ-SUBSTITUES, PROCEDE DE PREPARATION ASSOCIE ET MEDICAMENTS RENFERMANT CES DERNIERS EN TANT QUE PRINCIPE ACTIF
WO2003028712A2 (en) 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes

Also Published As

Publication number Publication date
EP1891961B1 (en) 2009-09-16
CY1109539T1 (el) 2014-08-13
AU2005329287B2 (en) 2011-01-27
CA2601557A1 (en) 2006-09-21
ES2334924T3 (es) 2010-03-17
US20090042831A1 (en) 2009-02-12
AU2005329287A1 (en) 2006-09-21
ATE442854T1 (de) 2009-10-15
HRP20090646T1 (hr) 2010-01-31
US7820637B2 (en) 2010-10-26
PT1891961E (pt) 2009-12-17
DE602005016729D1 (de) 2009-10-29
PL1891961T3 (pl) 2010-02-26
EP1891961A1 (en) 2008-02-27
JP2008533107A (ja) 2008-08-21
MX2007011327A (es) 2008-01-28
BRPI0520129A2 (pt) 2009-04-28
WO2006097547A1 (es) 2006-09-21
CN101141970A (zh) 2008-03-12
DK1891961T3 (da) 2009-12-21
SI1891961T1 (sl) 2010-01-29

Similar Documents

Publication Publication Date Title
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
PT1891961E (pt) Uso de 5'-metiltioadenosina (mta) na prevenção e/ou no tratamento de doenças auto-imunes e/ou rejeição de transplante
MY144318A (en) Methods of treating hiv infection.
HK1082435A1 (en) Compositions and methods for coating medical implants
PL2026803T3 (pl) Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
WO2006034001A3 (en) Methods of treating hiv infection
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
EP1676512A3 (en) Skin treatment articles and methods
FR13C0062I1 (sr)
WO2002064096A3 (en) Methods of using pyrimidine-based antiviral agents
IL174636A0 (en) Compositions containing anti-scarring agents and medical implants incorporating the same
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
EP1893216A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
HK1111083A1 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
TWI340639B (en) Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
WO2007130509A3 (en) Pyrroloquinoline quinones and use thereof
WO2004091436A3 (en) Methods and compositions for treating ocular disease
PT1590046T (pt) Composição para o tratamento de hiv ou sida
WO2006079121A3 (en) Methods of treating disease with glycosylated interferon
GB2401044B (en) A composition for use in the treatment or prophylaxis of a skin condition in a subject
MY157231A (en) Aminocyclohexyl ether compounds and uses thereof
TW200509940A (en) Pharmaceutical composition